Gsk (GSK) Exchange Rate Effect (2009 - 2026)
Gsk (GSK) posted quarterly Exchange Rate Effect of $2.7 million for Q1 2026, up 119.46% year-over-year from $1.2 million in Q1 2025, and up 105.48% quarter-over-quarter from -$49.2 million in Q4 2025.
Gsk (GSK) Exchange Rate Effect (2009 - 2026) Analysis & Trends
Gsk's Exchange Rate Effect history runs 18 years deep, the most recent figure standing at $2.7 million for Q1 2026.
- In Q1 2026, Exchange Rate Effect rose 119.46% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at -$95.0 million (up 47.74% YoY), while the FY2025 annual figure was -$25.1 million, up 63.71% from the prior year.
- Exchange Rate Effect for Q1 2026 stood at $2.7 million, up from -$49.2 million in the prior quarter.
- The five-year high for Exchange Rate Effect was $97.4 million in Q4 2022, with the low at -$109.2 million in Q4 2023.
- The 5-year median for Exchange Rate Effect is -$24.1 million (2024), against an average of -$17.0 million.
- The sharpest annual moves came in 2022 and 2023: Exchange Rate Effect surged 312.41% in 2022, then sank 334.01% in 2023.
- Gsk's Exchange Rate Effect stood at $97.4 million in 2022, then sank by 212.19% to -$109.2 million in 2023, then jumped by 68.27% to -$34.7 million in 2024, then plunged by 42.02% to -$49.2 million in 2025, then surged by 105.48% to $2.7 million in 2026.
- Business Quant data shows GSK's Exchange Rate Effect at $2.7 million in Q1 2026, -$49.2 million in Q4 2025, and -$13.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.19 Bn | 631.43 Bn | 17.26 Bn | 5.00 Mn |
| 2 | AbbVie | 470.70 Bn | 464.13 Bn | 12.70 Bn | -7.00 Mn |
| 3 | Merck | 379.55 Bn | 372.41 Bn | 12.21 Bn | -37.00 Mn |
| 4 | Novartis Ag | 302.93 Bn | 295.24 Bn | 11.24 Bn | -18.00 Mn |
| 5 | Astrazeneca | 257.73 Bn | 252.83 Bn | 12.86 Bn | 9.00 Mn |
| 6 | Amgen | 236.90 Bn | 222.91 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 182.87 Bn | 179.69 Bn | 6.22 Bn | -19.00 Mn |
| 8 | Pfizer | 161.71 Bn | 150.01 Bn | 10.94 Bn | -4.00 Mn |
| 9 | Gsk | 105.60 Bn | 101.43 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.13 Bn | 47.75 Bn | 10.79 Bn | 11.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.70 Mn |
| Mar 31, 2026 | 2.70 Mn |
| Dec 31, 2025 | -49.22 Mn |
| Dec 31, 2025 | -49.22 Mn |
| Mar 31, 2025 | -13.85 Mn |
| Mar 31, 2025 | -13.85 Mn |
| Dec 31, 2024 | -34.65 Mn |
| Dec 31, 2024 | -34.65 Mn |
| Mar 31, 2024 | -24.10 Mn |
| Mar 31, 2024 | -24.10 Mn |
| Dec 31, 2023 | -109.22 Mn |
| Dec 31, 2023 | -109.22 Mn |
| Mar 31, 2023 | -37.68 Mn |
| Mar 31, 2023 | -37.68 Mn |
| Dec 31, 2022 | 97.35 Mn |
| Dec 31, 2022 | 97.35 Mn |
| Mar 31, 2022 | 16.10 Mn |
| Mar 31, 2022 | 16.10 Mn |
| Dec 31, 2021 | -45.83 Mn |
| Dec 31, 2021 | -45.83 Mn |